EYPT

EyePointA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.20

Analysis reference price unavailable

Analysis 2026-10-20 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-10-20 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.15

Analysis reference price unavailable

Analysis 2026-10-20 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-20

AI commentary

The $0.44 October 19 packet anchor follows a severe selloff; contemporaneous coverage reported EYPT near $0.45, down about 86% from a $3.14 prior close, after LUCIA's miss. Jefferies' reported downgrade and target cut are a negative revision signal, but a complete post-print revision set is unavailable. No supported social, options, short-interest or employee readings were supplied; zeroes in those fields denote unavailable data, not neutral observations. Market and analyst reaction

RankAlpha Sentiment Codex - 2026-10-20

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-19catalystRepricing after LUCIA's failed primary endpointHigh impact

LUCIA did not demonstrate non-inferiority to aflibercept in wet AMD, following LUGANO's failure on the same primary endpoint. LUCIA met treatment-burden secondary endpoints, but EyePoint will analyze whether any wet-AMD path remains. Further analyst revisions could extend volatility; the move estimate is a judgment, not guidance. [#SEC-8K-2026-10-19] SEC-filed LUCIA release

2027-06-30eventRestructuring and cash preservationMedium impact

EyePoint plans to cut approximately 53% of positions, with most reductions expected in Q4 2026 and completion in H1 2027. It estimates $30 million in annualized savings against approximately $9 million in separation charges. Execution and the resulting cash runway need verification. [#8-K-2026-10-19] SEC-filed strategic-prioritization release

2027-12-31catalystCOMO and CAPRI pivotal DME readoutsHigh impact

EyePoint has shifted its focus to DURAVYU in diabetic macular edema and expects topline results from both Phase 3 trials in Q4 2027. Positive Phase 2 VERONA results support testing the indication but do not establish Phase 3 success; financing needs before the readouts remain uncertain. [#SEC-8K-2026-10-19] SEC-filed LUCIA release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-20 • Updated nightlySource: Internal modelMethodology